Investments

We’re immensely proud of our portfolio. We partner with companies, often in the early stage, to build strong management teams and to ensure our CEOs and entrepreneurs have access to our network and resources to accelerate the advancement of their assets.

Brandon BioCatalyst plays an active, ‘hands on’ role, working closely with the Member Institutes to identify promising opportunities, ‘working them up’, completing due diligence and in many cases, assisting with the establishment of the start-up company. Importantly, we then guide early-stage investments through the development process to next round financing, a trade-sale, partnering, an IPO or into stand-alone, growing businesses. Brandon BioCatalyst invests in opportunities originating from its member medical research institutes or research hospitals. Each Member Institute selects a representative for Brandon BioCatalyst’s Investment Review Committee (IRC), the body which provides a peer review assessment of investment proposals.

To date, Brandon BioCatalyst has supported more than 50 promising start-up companies, with more than 85 percent of them founded by the first investment from Brandon BioCatalyst .

Allay Therapeutics
Allay Therapeutics

Combining non-opioid analgesics and biopolymers to deliver weeks of localised pain management

View Project
Amaroq Therapeutics
Amaroq Therapeutics

Targeting long non-coding RNAs for next generation cancer therapies

View Project
Ankere Therapeutics
Ankere Therapeutics

Developing novel therapeutics for inflammatory diseases

View Project
Aravax
Aravax

Creating the first safe and rapidly effective treatment for peanut allergy

View Project
Azura Ophthalmics
Azura Ophthalmics

Developing a novel therapy for the treatment of Meibomian Gland Dysfunction

View Project
Certa Therapeutics
Certa Therapeutics

Developing novel anti-fibrotic therapies for the treatment of scarring associated with chronic kidney disease

View Project
Cincera Therapeutics
Cincera Therapeutics

Targeting fibrotic and inflammatory indications associated with type 2 diabetes and metabolic syndrome with an initial focus on liver fibrosis

View Project
Currus Biologics
Currus Biologics

Developing the next generation of CAR-T cell therapies to treat solid cancers

View Project
Denteric
Denteric

Developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis)

View Project
EBR Systems
EBR Systems

Developing therapies for patients with cardiac rhythm diseases and heart failure using wireless cardiac stimulation

View Project
Ena Respiratory
Ena Respiratory

Developing therapies for respiratory infections in patients with asthma and COPD

View Project
George Medicines
George Medicines

George Medicines is an innovative late-stage drug development company focused on the large, expanding and underserved market for the management of non-communicable diseases (NCDs)

View Project